Scynexis Inc. (NASDAQ:SCYX)’s share price was down 2.7% during mid-day trading on Thursday . The company traded as low as $2.16 and last traded at $2.19, with a volume of 326,452 shares traded. The stock had previously closed at $2.25.

A number of equities analysts have issued reports on SCYX shares. Zacks Investment Research raised shares of Scynexis from a “hold” rating to a “buy” rating and set a $3.25 target price on the stock in a report on Wednesday, June 15th. Needham & Company LLC reissued a “buy” rating and issued a $16.00 target price on shares of Scynexis in a report on Thursday, June 9th. Canaccord Genuity reissued a “buy” rating on shares of Scynexis in a report on Thursday, June 9th. Finally, Brean Capital reissued a “buy” rating and issued a $16.00 target price on shares of Scynexis in a report on Thursday, June 9th. Six analysts have rated the stock with a buy rating, Scynexis presently has an average rating of “Buy” and an average target price of $12.71.

The firm’s market cap is $30.32 million. The firm’s 50 day moving average price is $2.98 and its 200-day moving average price is $4.18.

Scynexis (NASDAQ:SCYX) last posted its quarterly earnings data on Monday, May 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.11. Equities analysts forecast that Scynexis Inc. will post ($2.27) EPS for the current year.

In related news, CFO Eric Francois acquired 15,000 shares of the company’s stock in a transaction dated Friday, June 24th. The shares were bought at an average price of $2.39 per share, for a total transaction of $35,850.00. Following the acquisition, the chief financial officer now owns 15,000 shares in the company, valued at approximately $35,850. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Gonzalez David Angulo acquired 36,950 shares of the company’s stock in a transaction dated Thursday, June 30th. The shares were bought at an average price of $2.22 per share, for a total transaction of $82,029.00. Following the acquisition, the insider now owns 8,850 shares in the company, valued at approximately $19,647. The disclosure for this purchase can be found here.

SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.